L-Arginine restores splenocyte functions after trauma and hemorrhage potentially by improving splenic blood flow.
Several studies indicate that immune responses are markedly depressed early after onset of hemorrhage. Decreased organ blood flow has been implicated in the pathophysiology of altered immune responses after trauma-hemorrhage. In this regard, administration of L-arginine has been shown to restore depressed intestinal and hepatic blood flow after trauma-hemorrhage, probably due to provision of substrate for constitutive nitric oxide synthase (cNOS). It remains unknown, however, whether administration of L-arginine also ameliorates depressed splenic blood flow and whether this agent has any salutary effects on depressed splenocyte functions after trauma-hemorrhage. Male rats underwent sham operation or laparotomy and were bled to and maintained at a mean arterial blood pressure of 40 mmHg until 40% of maximum shed blood volume (MBV) was returned as Ringer lactate (RL). Hemorrhaged rats were then resuscitated with RL (4 times MBV over 1 h). During resuscitation, rats received 300 mg/kg L-arginine or saline (vehicle) intravenously; 4 h later, splenic blood flow, splenocyte proliferation, and splenocyte interleukin (IL)-2 and IL-3 were determined. Administration of L-arginine improved depressed splenic blood flow and restored depressed splenocyte functions after trauma-hemorrhage. Therefore, provision of L-arginine during resuscitation after trauma-hemorrhage should be considered a novel and safe approach for improving splenic organ blood flow and depressed splenocyte functions under such conditions.
Angele
M K
MK
Center for Surgical Research and Department of Surgery, Brown University School of Medicine and Rhode Island Hospital, Providence, Rhode Island 02903, USA.
Smail
N
N
Knöferl
M W
MW
Ayala
A
A
Cioffi
W G
WG
Chaudry
I H
IH
D000818:Animals; D001120:Arginine / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005938:Glucocorticoids / Q000097:blood; D006146:Guanidines / Q000494:pharmacology; D006470:Hemorrhage / Q000188:drug therapy* / Q000503:physiopathology; D007376:Interleukin-2 / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013152:Splanchnic Circulation / Q000187:drug effects* / Q000502:physiology; D013154:Spleen / Q000098:blood supply / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D014947:Wounds and Injuries / Q000188:drug therapy* / Q000503:physiopathology
D004791:Enzyme Inhibitors; D005938:Glucocorticoids; D006146:Guanidines; D007376:Interleukin-2; D001120:Arginine; C004479:pimagedine